Hi ohm. One of the things on that list was "any m
Post# of 148179
On the one hand, I could argue that CD12 not meeting its primary endpoint is a material impairment because it will change the share price and value of the company immediately and investors would want this information in order to make decisions.
On the other hand, I could argue that CD12 results, if not positive, are not a material impairment because HIV has a strong chance of approval and that is really what CYDY is all about for the immediate future, HIV, and covid was really an after-thought/happy accident for CYDY anyway.